Vaderis Therapeutics
Develops an oral AKT inhibitor for hereditary hemorrhagic telangiectasia
$152MSeries B
Role not disclosedLoading investors…
Activity from announced rounds
Develops an oral AKT inhibitor for hereditary hemorrhagic telangiectasia
Develops bispecific antibody therapies for retinal vascular diseases including diabetic macular edema and wet AMD
Pitching TCGX? Send the deck from a free RoundOS data room and see which pages they read.
Create a free room